AstraZeneca's Kendall Square R&D center in Cambridge, MA. (Credit: Pickard Chilton)
November 12, 2024 07:08 AM ESTUpdated 08:07 AM
R&D
Manufacturing

As­traZeneca bud­gets an­oth­er $2B to boost man­u­fac­tur­ing and R&D in US

Anna Brown

News Reporter

Among a flur­ry of third-quar­ter up­dates on Tues­day, As­traZeneca said it is ear­mark­ing an ad­di­tion­al $2 bil­lion to add 1,000 new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times